Safety Testing Expansion EPISKIN specializes in in vitro reconstructed human tissues and validated screening tests as alternatives to animal use, indicating readiness to expand collaborations with cosmetics, pharmaceutical, and chemical companies seeking robust safety assessment platforms.

New Model Deployments Recent launches of SkinEthic RHE in 1 cm2 format and SkinEthic HBE demonstrate a growing portfolio of tissue models, presenting upsell opportunities to clients needing more scalable or diverse in vitro skin representations.

Training as Upsell With introduced 3D model training sessions and validated protocols, there is a potential to monetize education offerings alongside core tissue products, strengthening adoption and customer success.

Global Market Fit EPISKIN targets global cosmetics, pharmaceutical, and chemical brands, indicating potential for enterprise-level partnerships, long-term contracts, and regional expansion to serve ongoing client R&D programs.

Financial Growth Path Current revenue is under one million with a mid-sized employee base, suggesting opportunities to package scalable service models, maintenance in vitro testing programs, and volume-based pricing to accelerate growth.